Regeneron Pharmaceuticals Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals Inc. (REGN): $728.18

39.31 (+5.71%)

POWR Rating

Component Grades













Add REGN to Watchlist
Sign Up

Industry: Biotech



in industry


  • REGN scores best on the Quality dimension, with a Quality rank ahead of 92.12% of US stocks.
  • REGN's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • REGN's current lowest rank is in the Growth metric (where it is better than 4.49% of US stocks).

REGN Stock Summary

  • With a market capitalization of $74,790,609,724, REGENERON PHARMACEUTICALS INC has a greater market value than 97.57% of US stocks.
  • REGN's went public 31.51 years ago, making it older than 85.02% of listed US stocks we're tracking.
  • The volatility of REGENERON PHARMACEUTICALS INC's share price is greater than that of just 13.31% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to REGENERON PHARMACEUTICALS INC, a group of peers worth examining would be AMAT, LRCX, SNPS, CDNS, and VRTX.
  • REGN's SEC filings can be seen here. And to visit REGENERON PHARMACEUTICALS INC's official web site, go to

REGN Valuation Summary

  • REGN's price/sales ratio is 5.3; this is 178.95% higher than that of the median Healthcare stock.
  • REGN's EV/EBIT ratio has moved up 19.4 over the prior 243 months.

Below are key valuation metrics over time for REGN.

Stock Date P/S P/B P/E EV/EBIT
REGN 2022-09-23 5.3 3.7 13.4 11.8
REGN 2022-09-22 5.3 3.6 13.2 11.6
REGN 2022-09-21 5.2 3.6 13.1 11.6
REGN 2022-09-20 5.4 3.7 13.5 11.9
REGN 2022-09-19 5.5 3.8 13.7 12.1
REGN 2022-09-16 5.4 3.7 13.6 12.0

REGN Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 95.83%.
  • Its 4 year revenue growth rate is now at 68.65%.
  • The 2 year cash and equivalents growth rate now stands at 51.51%.
REGN's revenue has moved up $6,605,103,000 over the prior 33 months.

The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 14,226.8 8,452.2 5,686.8
2022-03-31 16,508.1 8,514.5 7,933.6
2021-12-31 16,071.7 7,081.3 8,075.3
2021-09-30 13,542.9 5,939.8 6,995.5
2021-06-30 12,384.1 2,271.9 6,205.4
2021-03-31 9,197.6 2,588.6 4,003.8

REGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • REGN has a Quality Grade of B, ranking ahead of 86.94% of graded US stocks.
  • REGN's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
  • JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.

The table below shows REGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.868 0.456
2021-03-31 0.562 0.868 0.315
2020-12-31 0.536 0.868 0.292
2020-09-30 0.540 0.880 0.283
2020-06-30 0.543 0.882 0.282
2020-03-31 0.553 0.897 0.221

REGN Price Target

For more insight on analysts targets of REGN, see our REGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $683.25 Average Broker Recommendation 1.52 (Moderate Buy)

REGN Stock Price Chart Interactive Chart >

Price chart for REGN

REGN Price/Volume Stats

Current price $728.18 52-week high $754.67
Prev. close $688.87 52-week low $538.01
Day low $694.64 Volume 548,773
Day high $734.55 Avg. volume 708,093
50-day MA $640.18 Dividend yield N/A
200-day MA $637.19 Market Cap 79.38B

Regeneron Pharmaceuticals Inc. (REGN) Company Bio

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester CountyNew York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. (Wikipedia:Source)

REGN Latest News Stream

Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream

Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock

Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...

Yahoo | October 1, 2022

Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The data were presented in a late-breaking session at the American Academy of Ophthalmology (AAO) annual meeting in Chicago and will support the s

Yahoo | September 30, 2022

Illumina Aims to Push Genetics Beyond the Lab With $200 Genome

(Bloomberg) -- Illumina Inc. says it can read a person’s entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite Hurri

Yahoo | September 29, 2022

Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates

Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.

Yahoo | September 29, 2022

Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

Yahoo | September 29, 2022

Read More 'REGN' Stories Here

REGN Price Returns

1-mo 25.41%
3-mo 22.06%
6-mo 2.80%
1-year 27.57%
3-year 157.37%
5-year 59.67%
YTD 15.31%
2021 30.72%
2020 28.66%
2019 0.53%
2018 -0.65%
2017 2.42%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6929 seconds.